Oculis (NASDAQ:OCS) Shares Down 4.3% – What’s Next?

Oculis Holding AG (NASDAQ:OCS)’s stock price fell 4.3% during mid-day trading on Monday . The stock traded as low as $15.34 and last traded at $15.35. 10,193 shares changed hands during trading, a decline of 72% from the average session volume of 36,993 shares. The stock had previously closed at $16.04.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Oculis in a research note on Monday, November 11th. Five analysts have rated the stock with a buy rating, According to MarketBeat, Oculis currently has a consensus rating of “Buy” and an average price target of $29.20.

Oculis Stock Down 5.4 %

The company has a market cap of $614.39 million, a P/E ratio of -8.31 and a beta of -0.16. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. The business’s fifty day moving average is $14.96 and its two-hundred day moving average is $12.90.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.